Atheroembolism during PTRAS has been postulated as a potential cause for this acute renal function worsening. The aim of this study was to report on the feasibility, safety, and early outcomes of PTRAS in a series
of patients with SFK using distal embolic protection (DEP).
Methods: All PTRAS procedures in SFKs performed under DEP between June 2002 and September 2007 were reviewed. Renal function, blood pressure, and the number of anti-hypertensive medications were assessed pre- and post-intervention. Renal function improvement and deterioration were defined as a 20% increase and decrease in serum creatinine, respectively compared with preoperative values. Primary and primary assisted patency rates were also calculated. Statistical differences WH-4-023 research buy between values before and after intervention were determined by the Student t test and statistical significance was taken at P < .05.
Results: Protected PTRAS was performed in 14 patients with a SFK (9 men, 6 women, mean age 65.6 +/- 6.8 years). All patients were hypertensive and had varying degrees of azotemia. Mean pre-intervention stenosis degree was 86.8% +/- 7.8%. Immediate technical success
was obtained in 100% of the patients. Renal function was cured (7.1%), improved (50%), or Lonafarnib in vitro stabilized (42.9%) in all 14 (100%) patients after the procedure and no deterioration was noticed ill any LDK378 cost patient at 6-month follow-up. Pre- and postintervention serum creatinine levels were 3.01 +/- 1.15 mg/dL and 2.16 +/- 0.68 mg/dL, respectively, (P = .02). Hypertension was improved in 6 (42.9%)
patients and stabilized in the remaining 8 (57.1%). Primary patency was 100% and 90% at 1 and 3 years, respectively, while primary assisted patency remained 100% for the whole follow-up period (mean, 31.8 +/- 19.4 months).
Conclusion: These findings suggest that in patients with a SFK, protected PTRAS represents a safe and effective treatment for halting the progression of renal dysfunction to renal loss and warrants further investigation. (J Vasc Surg 2008;48: 1414-22.)”
“Introduction: Ubiquicidin (UBI) 29-41 is a cationic synthetic antimicrobial peptide fragment that binds preferentially with the anionic microbial cell membrane at the site of infection. This study was conducted to evaluate the potentiality of [Tc-99m/Tricine/HYNIC0]UBI 29-41 prepared from lyophilized kits as an infection imaging agent in humans.
Methods: Seven patients (5 males and 2 females; mean age=55 years; age range=35-75 years) with Suspected bone or soft-tissue infections participated in this study.